HeraMED Limited announced outstanding clinical study results that confirm the accuracy of the HeraBEAT device against a hospital grade Cardiotocography CTG machine. Furthermore, the results confirmed the ease of use and user satisfaction by expectant mothers at the clinic, and at home, as well as the effective electronic transmission of the foetal heart rate (FHR) trace by the mother to the antenatal care team for review and consultation. The clinical study was undertaken at Joondalup Health Campus (JHC), Western Australia and led by Associate Professor Paul Porter (the "Study"). The Study was designed to evaluate the usability, accuracy, and reliability of the HeraBEAT device, by expectant mothers, initially at the antenatal clinic and then at home. About the Results: The accuracy of the HeraBEAT device was found to be excellent when compared to the industry gold standard CTG (Phillips Avalon) machine. The device was used 126 times and the limits of agreement (95%) were between -1.5, +0.9 BPM and a mean difference of approximately -0.3 BMP. The FHR was detected on 100% of occasions by clinicians (n=52) and importantly, the FHR was detected on 100% of occasions by the expectant mothers when using the device without assistance. These results were achieved both in the clinic (42 occasions) and at home (32 occasions). The average time to locate the FHR by expectant mothers at home was 1.1 minutes with an average total FHR tracing time of 4.4 minutes. The FHR trace was deemed clinically interpretable (as assessed by obstetric staff) in 100% of clinician performed assessments and in 97% of maternal home use. Using the international medical standard System Usability Scale (SUS) to usability of expectant mothers, the device was very well-reviewed by the pregnant women, ranking in the 96-100% percentile for usability and user satisfaction. Commercialisation Strategy: The HeraBEAT device forms the backbone of HeraMED's comprehensive HeraCARE SaaS and IoT platform, a digital hybrid maternity care solution. HeraMED's proprietary technology has already obtained TGA (Australia) and CE (Europe) approvals for OTC (over the counter) home use as well as FDA 510K clearance for home use under prescription in the US. The clinical study undertaken by Joondalup Health Campus reflects the Company's well-defined strategy to align itself with leading healthcare providers and medical institutions to gain medical validation and to complement and improve the care currently offered by obstetricians and healthcare providers. HeraMED is in discussions with many leading healthcare providers around the world to undertake paid pilots to assess the HeraCARE platform to enhance their existing care models for expectant mothers. These results can now be leveraged into all future commercial opportunities and strengthen the Company's position when discussing future commercial agreements.